Zynlonta® (loncastuximab tesirine-lpyl)
for Lymphoma

Zynlonta (loncastuximab tesirine-lpyl) is used to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior treatments. It is an antibody-drug conjugate (ADC) that targets CD19 on B-cell cancer cells. Once bound, it delivers an anti-cancer drug directly into the cell, causing cell death. This targeted approach helps reduce tumor size and limits toxicity compared to traditional chemotherapy.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Lymphoma